Bundesrepublik Deutschland

Other

Bundersrepublik Deutschland, Letzvertreten Durch Den Präsidenten Des Paul-ehrlich-instituts

Bundesrepublik Deutschland, Letztvertreten Durch Den Prasidenten Des Paul-ehrlich-instituts

Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-ehrlich-instituts Prof. Dr. Johannes Löwer

Klaus Cichutek

Roberto Cattaneo

Christian Buchholz

Mario Perkovic

Matthias Schweizer

Martin Engelstadter

Martin Engelstaedter

Heike Merget-Millitzer

Sabrina Funke

Sabrina Kneissl

Michael Muehlebach

Carsten Münk

Daniela Marino

The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation ofF and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.

Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening

The invention relates to retroviral vectors (known as lentiviral vectors), which are used to transfer genes into cells that are at cell cycle stage G0, to methods for their production and to the use thereof for transferring genes into mammalian cells. Said vectors are derived from SIVsmmPBj14 (simian immunodeficiency virus) of the sooty mangabey monkey, strain PBj 14.

Lentiviral vectors derived from SIVsmm/PBj14, method for their production and uses thereof

The invention relates to cell-specific retroviral vectors with antibody recognition domains (scFv), which are suitable for cell-specific transduction of a selected mammal cell type (cell targeting), to methods for the production of the cell-specific retroviral vectors and to the use thereof in gene transfers into selected cells. The invention further relates to retroviral packaging cells to obtain cell-specific vectors according to the present invention.

Cell-specific retroviral vectors with antibody domains and method for the production thereof for selective gene transfer

The invention relates to gene transfer into human T cells using novel retroviral scFv cell targeting vectors and using these vectors for the treatment of T-cell-associated diseases.

Gene transfer in human lymphocytes using retroviral scFv cell targeting

The invention relates to pseudo-typed retroviral vectors having modified surface capsid proteins suitable for cell-specific transduction of a selected mammalian cell type (cell targeting), methods for the preparation of the cell-specific pseudo-typed retroviral vectors and to their use in gene transfer into selected cells.

Pseudo-type retroviral vectors with modifiable surface capsid proteins

Growing community of inventors

Langen, Germany

Klaus Cichutek